Researchers at Dana-Farber Cancer Institute have developed a novel technique to prevent relapse after CAR T-cell therapy for cancer.
Researchers at Dana-Farber Cancer Institute have developed a new technique, CAR-Enhancer (CAR-E), to address the relapse issue seen in CAR T-cell therapies for cancer treatment.
The CAR-E platform enhances the activity and persistence of CAR T cells in the body, allowing them to continuously fight tumor cells and form a memory of the cancer for potential future recurrences.
This approach has successfully eradicated all tumor cells in patient-derived laboratory cancer cell lines, paving the way for upcoming clinical trials in human patients.
CAR-E therapy promotes the proliferation and diversification of CAR T cells, resulting in a more effective immune response to cancer.
This innovative therapy could potentially reduce the need for large quantities of CAR T cells, decrease the risk of side effects, and be easily integrated into existing CAR T-cell treatment protocols.
A new study from Dana-Farber Cancer Institute introduces a promising technique to address the limitations of CAR T-cell therapies, which often result in relapse for many cancer patients. The technique involves enhancing CAR T cells’ activity and persistence in the body, allowing them to remain in battle mode until all tumor cells are eliminated. This new approach, called CAR-Enhancer (CAR-E), also enables CAR T cells to form a memory of the cancer cells, potentially preventing recurrence.
By delivering a novel therapeutic agent, the CAR-E platform, to CAR T cells, researchers were able to significantly improve the ability of these cells to eradicate tumor cells in patient-derived laboratory cell lines and animal models. The therapy not only led to the complete clearance of tumor cells but also generated diverse types of CAR T cells that could provide a more effective immune response to cancer. Clinical trials of this new approach are expected to begin soon, offering new hope for cancer patients receiving CAR T-cell therapy.
